B cells and humoral immunity in melanoma: regulatory and autoimmune-like features and implications for immunotherapy
{{output}}
B cells and the humoral immune response are increasingly recognized as critical modulators of melanoma progression and immunotherapy outcomes. While checkpoint inhibitor (CPI) therapy was developed to target T cell exhaustion mechanisms, emerging evidence high... ...
